



Talvey in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

ONCOLOGY · RELAPSED/REFRACTORY MULTIPLE MYELOMA

The clinical situation

Talvey (talquetamab-tgvs) is an FDA-approved GPRC5D×CD3 bispecific antibody from Janssen for relapsed/refractory multiple myeloma — including patients whose disease has progressed on BCMA-directed therapies. Administered subcutaneously on a step-up schedule with priming doses followed by weekly or bi-weekly target dosing to reduce cytokine release syndrome risk. Step-up is typically inpatient; dysgeusia and skin/nail effects are class-specific and manageable with supportive care.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist confirms relapsed/refractory myeloma, prior BCMA exposure where relevant, and fitness for bispecific therapy.
- 2 Haematology unit confirmed.** A UAE tertiary haematology unit with step-up admission capacity and CRS/neurotoxicity monitoring accepts the case.
- 3 MoHAP named-patient application.** Clinical rationale, line history, product details, and GPRC5D-specific adverse-event surveillance plan are filed (DoH Abu Dhabi / DHA Dubai per facility).
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; cold-chain shipment with temperature monitoring.
- 5 Arrival, step-up & maintenance dosing.** The hospital pharmacy receives product and releases doses for the step-up admission and subsequent outpatient injections.

Indicative economics

Reference US cash-pay range: USD 38,000–46,000 per 4-week maintenance supply; drug-only reference. Reserve Meds provides a transparent delivered quote at intake.

Indicative first-dose timing

7–14 days from a complete MoHAP application to first step-up dose, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP review. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through intake, step-up, and maintenance. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Talvey × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/talvey-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team